Walenga JM - Search Results

1

Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.

Ahmad S, Untch B, Haas S, Hoppensteadt DA, Misselwitz F, Messmore HL, Walenga JM, Fareed J. Ahmad S, et al. Among authors: walenga jm. Mol Cell Biochem. 2004 Mar;258(1-2):163-70. doi: 10.1023/b:mcbi.0000012852.60500.30. Mol Cell Biochem. 2004. PMID: 15030181

2

Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model.

Doutremepuich C, Lalanne MC, Doutremepuich F, Walenga J, Fareed J, Breddin HK. Doutremepuich C, et al. Haemostasis. 1991;21 Suppl 1:99-106. doi: 10.1159/000216269. Haemostasis. 1991. PMID: 1894201

3

Neonatal and maternal platelets: activation at time of birth.

Suarez CR, Gonzalez J, Menendez C, Fareed J, Fresco R, Walenga J. Suarez CR, et al. Am J Hematol. 1988 Sep;29(1):18-21. doi: 10.1002/ajh.2830290105. Am J Hematol. 1988. PMID: 2972197

4

Relationship between postsurgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices.

Summaria L, Caprini JA, McMillan R, Sandesara J, Axelrod CA, Mueller ME, Vagher JP, Walenga J, Fareed J. Summaria L, et al. Am Surg. 1988 Mar;54(3):156-60. Am Surg. 1988. PMID: 3279880

5

Protein C antigen deficiency and warfarin necrosis.

Rose VL, Kwaan HC, Williamson K, Hoppensteadt D, Walenga J, Fareed J. Rose VL, et al. Am J Clin Pathol. 1986 Nov;86(5):653-5. doi: 10.1093/ajcp/86.5.653. Am J Clin Pathol. 1986. PMID: 3776917

6

Automated instrumentation and the laboratory diagnosis of bleeding and thrombotic disorders.

Walenga J, Fareed J, Bermes EW Jr. Walenga J, et al. Semin Thromb Hemost. 1983 Jul;9(3):172-93. doi: 10.1055/s-2007-1005020. Semin Thromb Hemost. 1983. PMID: 6351253 Review. No abstract available.

7

Synthetic substrate assays of the coagulation enzymes and their inhibitors. Comparison with clotting and immunologic methods for clinical and experimental usage.

Messmore HL Jr, Fareed J, Kniffin J, Squillaci G, Walenga J. Messmore HL Jr, et al. Ann N Y Acad Sci. 1981;370:785-97. doi: 10.1111/j.1749-6632.1981.tb29785.x. Ann N Y Acad Sci. 1981. PMID: 7023331 Review. No abstract available.

8

Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin.

Kijowski R, Hoppensteadt D, Walenga J, Borris L, Lassen MR, Fareed J. Kijowski R, et al. Thromb Res. 1994 Apr 1;74(1):53-64. doi: 10.1016/0049-3848(94)90035-3. Thromb Res. 1994. PMID: 8029808 Clinical Trial.

9

Successful Coronary Interventions Performed with Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia and Thrombosis Syndrome.

Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga J, Joffrion JL, Wrona L, Johnson SA, Schwarz RP Jr, McKiernan T. Lewis BE, et al. J Invasive Cardiol. 1996 Nov;8(9):410-417. J Invasive Cardiol. 1996. PMID: 10785742

10

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.

Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Walenga JM, et al. Expert Opin Investig Drugs. 2002 Mar;11(3):397-407. doi: 10.1517/13543784.11.3.397. Expert Opin Investig Drugs. 2002. PMID: 11866668 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

288 results

Search Page

Filters